Vanda Pharmaceuticals (VNDA) Free Cash Flow (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Free Cash Flow of -$50.4 million for Q1 2026, down 50.19% on a YoY basis from -$101.3 million in Q1 2025, and down 70.87% sequentially from -$29.5 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Free Cash Flow (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Free Cash Flow data on file, last reported at -$50.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 50.19% year-over-year to -$50.4 million; the trailing twelve-month figure through Mar 2026 stood at -$127.3 million (down 121.8% YoY), and the FY2025 full-year result was -$110.4 million, down 579.76% from the prior year.
- Free Cash Flow fell to -$50.4 million in Q1 2026, from -$29.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $31.8 million in Q1 2023 to a low of -$50.4 million in Q1 2026.
- A 5-year average of -$7.8 million and a median of -$4.0 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow surged 699.6% in 2023 and slumped 1353.42% in 2025, its largest moves.
- Tracing VNDA's Free Cash Flow over 5 years: stood at $9.2 million in 2022, then sank by 143.54% to -$4.0 million in 2023, then jumped by 49.03% to -$2.0 million in 2024, then tumbled by 1353.42% to -$29.5 million in 2025, then tumbled by 70.87% to -$50.4 million in 2026.
- Business Quant data shows VNDA's Free Cash Flow at -$50.4 million in Q1 2026, -$29.5 million in Q4 2025, and -$31.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -50.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.44 Mn |
| Mar 31, 2026 | -50.44 Mn |
| Dec 31, 2025 | -29.52 Mn |
| Dec 31, 2025 | -29.52 Mn |
| Sep 30, 2025 | -31.79 Mn |
| Sep 30, 2025 | -31.79 Mn |
| Jun 30, 2025 | -15.55 Mn |
| Jun 30, 2025 | -15.55 Mn |
| Mar 31, 2025 | -33.58 Mn |
| Mar 31, 2025 | -33.58 Mn |
| Dec 31, 2024 | -2.03 Mn |
| Dec 31, 2024 | -2.03 Mn |
| Sep 30, 2024 | -14.74 Mn |
| Sep 30, 2024 | -14.74 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | 7.56 Mn |
| Mar 31, 2024 | 7.56 Mn |
| Dec 31, 2023 | -3.99 Mn |
| Dec 31, 2023 | -3.99 Mn |